“The goal of this study is not to divert funds away from cancers that are well supported, but rather expand funding for other cancers that aren’t getting enough support currently,” lead author Suneel ...

Heather Greenlee, ND, PhD, MPH, is a naturopathic doctor and the medical director of the Integrative Medicine Program at Fred Hutchinson Cancer Center in Seattle.

In the cancer realm, providers now have an arsenal of imaging tools at the ready, not only to detect cancer, but also to assess how far the disease has spread, target treatment while reducing harm to ...

Jennifer Ligibel, MD, a medical oncologist specializing in breast cancer at the Dana-Farber Cancer Institute in Boston who coauthored the ASCO guideline, was surprised by the research gaps. “It was ...

Christine Spencer, PhD, of the Parker Institute for Cancer Immunotherapy, McQuade and colleagues showed that melanoma patients responded better to checkpoint inhibitor immunotherapy if they ate a diet ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

Prostate cancer is the most common cancer in men besides skin cancer, and one in eight men will be diagnosed with the disease in their lifetime. About 313,780 men in the United States will develop ...

3 out of 4 patients went through a recent prior authorization, with half personally taking on tasks such as making phone calls or filing paperwork.

For years, most states have had so-called medical conscience laws that are mainly aimed at preventing providers or hospitals from having to participate in abortion. But conservative lawmakers in ...

That theme of normalcy turned upside down unfolds in the story of Seth Axelrod, PhD, too. But he’s had an edge in dealing with the emotional challenges of his own complex, difficult and often-changing ...

In new work published March 6 in Science Immunology, Fred Hutch Cancer Center scientists show there may be a way to give CAR T cells their own portable pit crew. This allows CAR T cells to rejuvenate ...

April 30, 2025• By Liz Highleyman Share Comments Print Advertisement Nearly three quarters of non-small-cell lung cancer (NSCLC) patients with HER2 mutations experienced tumor regression when treated ...